Pfizer Lung Cancer Drug Fails to Improve Survival in Trial

A clinical trial for Pfizer's lung cancer drug has failed to demonstrate an improvement in patient survival. This outcome marks a setback for the pharmaceutical company's efforts in lung cancer treatment.

23 Jun, 00:00 — 23 Jun, 00:00

Post Share

Sources

Showing 1 of 2 sources

japan-timesMostly Factual56d ago

Pfizer’s lung cancer drug trial fails to boost survival

Patients given the drug, called sigvotatug vedotin, didn't live significantly longer than those given standard therapy.

Read full article →

Coverage Timeline

First report: bloomberg · 22 Jun, 20:37|Full coverage: 2 · 3h|Window: 3h

Left-leaningCenterRight-leaning

bloomberg22 Jun, 20:37First to report

Pfizer’s Lung Cancer Drug Trial Fails to Boost Survival - Bloomberg.com

3h later

japan-times23 Jun, 00:00Latest update

PERSPECTA

PERSPECTA

Pfizer Lung Cancer Drug Fails to Improve Survival in Trial

Sources

Pfizer’s lung cancer drug trial fails to boost survival

Coverage Timeline

Pfizer’s Lung Cancer Drug Trial Fails to Boost Survival - Bloomberg.com

Pfizer’s lung cancer drug trial fails to boost survival

Related Stories

Another Death from West Nile Fever, 11 New HIV Cases Reported

Hyderabad Police Seize 36 Tonnes of Adulterated Ghee

Doctors Remove Record-Breaking 3.1kg Bladder Stone in Sri Lanka

Study Links New Music Album Releases to Increase in Road Fatalities

PERSPECTA